Contact activation products are new potential biomarkers to evaluate the risk of thrombotic events in systemic lupus erythematosus

Arthritis Research and Therapy

Volumn 15, Issue 6, 2013, Pages

  Bäck, Jennie ^a   Lood, Christian ^b   Bengtsson, Anders A ^b   Ekdahl, Kristina N ^a,c   Nilsson, Bo ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LINNAEUS UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 12; COMPLEMENT COMPONENT C1S INHIBITOR; DEXTRO PHENYLALANYLPIPECOLYLARGININE 4 NITROANILIDE; DEXTRO PROLYLPHENYLALANYLARGININE 4 NITROANILIDE; FIBRIN; FIBRINOGEN; HEPARIN DERIVATIVE; LEPIRUDIN; MELAGATRAN; PADGEM PROTEIN; PLASMA PROTEIN; THROMBIN; UNCLASSIFIED DRUG; SERINE PROTEINASE INHIBITOR;

ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ELECTROPHORESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRIN CLOT; FIBRINOGEN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PURIFICATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; THROMBOSIS; VEIN THROMBOSIS; WESTERN BLOTTING; ADULT; BLOOD; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XII; FEMALE; FIBRIN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RISK FACTORS; SERPINS; THROMBOSIS;

EID: 84888780786     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4399     Document Type: Article

References (27)

1. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcón G, Senécal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54:2550-2557. 10.1002/art.21955, 16868977.
2. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Côte R, Grover SA, Fortin PR, Clarke AE, Senécal JL. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44:2331-2337. 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I, 11665973.
3. Ratnoff OD, Margolius A. Hageman trait: an asymptomatic disorder of blood coagulation. Trans Assoc Am Physicians 1955, 68:149-154.
4. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005, 202:271-281. 10.1084/jem.20050664, 2213000, 16009717.
5. Joseph K, Shibayama Y, Ghebrehiwet B, Kaplan AP. Factor XII-dependent contact activation on endothelial cells and binding proteins gC1qR and cytokeratin 1. Thromb Haemost 2001, 85:119-124.
6. Joseph K, Shibayama Y, Nakazawa Y, Peerschke EI, Ghebrehiwet B, Kaplan AP. Interaction of factor XII and high molecular weight kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and with aggregated Abeta protein of Alzheimer's disease. Immunopharmacology 1999, 43:203-210. 10.1016/S0162-3109(99)00136-8, 10596854.
7. Mahdi F, Madar ZS, Figueroa CD, Schmaier AH. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 2002, 99:3585-3596. 10.1182/blood.V99.10.3585, 11986212.
8. Back J, Sanchez J, Elgue G, Ekdahl KN, Nilsson B. Activated human platelets induce factor XIIa-mediated contact activation. Biochem Biophys Res Commun 2010, 391:11-17. 10.1016/j.bbrc.2009.10.123, 19878657.
9. Ekdahl KN, Bengtsson AA, Andersson J, Elgue G, Ronnblom L, Sturfelt G, Nilsson B. Thrombotic disease in systemic lupus erythematosus is associated with a maintained systemic platelet activation. Br J Haematol 2004, 125:74-78. 10.1111/j.1365-2141.2004.04858.x, 15015972.
10. Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin SJ. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001, 115:451-459. 10.1046/j.1365-2141.2001.03101.x, 11703349.
11. Nagahama M, Nomura S, Ozaki Y, Yoshimura C, Kagawa H, Fukuhara S. Platelet activation markers and soluble adhesion molecules in patients with systemic lupus erythematosus. Autoimmunity 2001, 33:85-94. 10.3109/08916930108995993, 11264787.
12. Liu K, Li QZ, Delgado-Vega AM, Abelson AK, Sánchez E, Kelly JA, Li L, Liu Y, Zhou J, Yan M, Ye Q, Liu S, Xie C, Zhou XJ, Chung SA, Pons-Estel B, Witte T, de Ramón E, Bae SC, Barizzone N, Sebastiani GD, Merrill JT, Gregersen PK, Gilkeson GG, Kimberly RP, Vyse TJ, Kim I, D'Alfonso S, Martin J, Harley JB, Criswell LA. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans. J Clin Invest 2009, 119:911-923. 10.1172/JCI36728, 2662554, 19307730.
13. Ponticelli C, Meroni PL. Kallikreins and lupus nephritis. J Clin Invest 2009, 119:768-771. 10.1172/JCI38786, 2662572, 19348047.
14. Bertolaccini ML, Mepani K, Sanna G, Hughes GR, Khamashta MA. Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus. Ann Rheum Dis 2007, 66:533-536. 1856053, 17020907.
15. Jones DW, Gallimore MJ, MacKie IJ, Harris SL, Winter M. Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol 2000, 110:721-726. 10.1046/j.1365-2141.2000.02251.x, 10997986.
16. Abildgaard U. Antithrombin-early prophecies and present challenges. Thromb Haemost 2007, 98:97-104.
17. Back J, Lang MH, Elgue G, Kalbitz M, Sanchez J, Ekdahl KN, Nilsson B. Distinctive regulation of contact activation by antithrombin and C1-inhibitor on activated platelets and material surfaces. Biomaterials 2009, 30:6573-6580. 10.1016/j.biomaterials.2009.07.052, 19783299.
18. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277. 10.1002/art.1780251101, 7138600.
19. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996, 39:363-369. 10.1002/art.1780390303, 8607884.
20. Lood C, Amisten S, Gullstrand B, Jonsen A, Allhorn M, Truedsson L, Sturfelt G, Erlinge D, Bengtsson AA. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood 2010, 116:1951-1957. 10.1182/blood-2010-03-274605, 20538795.
21. Sanchez J, Elgue G, Riesenfeld J, Olsson P. Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin. Thromb Res 1998, 89:41-50. 10.1016/S0049-3848(97)00310-1, 9610759.
22. Ekdahl KN, Ronnblom L, Sturfelt G, Nilsson B. Increased phosphate content in complement component C3, fibrinogen, vitronectin, and other plasma proteins in systemic lupus erythematosus: covariation with platelet activation and possible association with thrombosis. Arthritis Rheum 1997, 40:2178-2186. 10.1002/art.1780401212, 9416855.
23. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306. 10.1111/j.1538-7836.2006.01753.x, 16420554.
24. Konings J, Govers-Riemslag JW, Philippou H, Mutch NJ, Borissoff JI, Allan P, Mohan S, Tans G, Ten Cate H, Ariens RA. Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 2011, 118:3942-3951. 10.1182/blood-2011-03-339572, 21828145.
25. de Pablo P, Ramirez A, Cortina E, de la Pena A, Zamora J, Izaguirre R, Amigo MC. Increased fibrin polymerization rate in patients with primary antiphospholipid syndrome and systemic lupus erythematosus. Clin Appl Thromb Hemost 2003, 9:221-225. 10.1177/107602960300900306, 14507110.
26. Pereira J, Alfaro G, Goycoolea M, Quiroga T, Ocqueteau M, Massardo L, Pérez C, Sáez C, Panes O, Matus V, Mezzano D. Circulating platelet-derived microparticles in systemic lupus erythematosus, Association with increased thrombin generation and procoagulant state. Thromb Haemost 2006, 95:94-99.
27. Govers-Riemslag JW, Smid M, Cooper JA, Bauer KA, Rosenberg RD, Hack CE, Hamulyak K, Spronk HM, Miller GJ, ten Cate H. The plasma kallikrein-kinin system and risk of cardiovascular disease in men. J Thromb Haemost 2007, 5:1896-1903. 10.1111/j.1538-7836.2007.02687.x, 17723129.